RAAS
RAAS
RAAS the company has been adhering to the quality policy
RAAS was founded in 1988 and listed on the Shenzhen Stock Exchange in 2008 (stock code: 002252), is a leading blood products company in Asia. Since its establishment 28 years ago, the company has been adhering to the quality policy of "safety, quality and efficiency", and has developed 11 products covering three categories of blood products: human blood protein, human immunoglobulin and coagulation factors, including human albumin, human immunoglobulin, static human immunoglobulin, hepatitis B human immunoglobulin, tetanus toxoid, and human immunoglobulin. Human immunoglobulin, rabies human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin, human fibrinogen, topical lyophilized human fibrin binder. Shanghai RAAS has been registered in nearly 20 countries, and is one of the few domestic manufacturers that can export blood products. Up to now, Shanghai RAAS has 33 plasma stations in China including those under construction, with an annual production capacity of 900 tons of plasma and more than 25 million vials of blood products.
- All
- News
- Analysis
- Research
Briefing Updated 4 hours ago
· Healthcare
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
In-depth
Healthcare
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Briefing May 11, 2022 03:53 PM
· Healthcare
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Briefing May 11, 2022 02:46 PM
· Healthcare
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Technology, Consumer Staples, Real EstateTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing May 11, 2022 02:18 PM
· Healthcare
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Briefing May 10, 2022 09:32 PM
· Healthcare
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Briefing Apr 27, 2022 06:47 PM
· Healthcare
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Briefing Apr 26, 2022 03:52 PM
· Healthcare
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Healthcare
R&D of Anti-COVID-19 Drugs is Blooming in China
Anti-epidemic stocks moved higher in early trading of the Hong Kong Stock Exchange today, with Kintor Pharma-B (Chinese: 开拓药业,09939:HK) and Shandong Xinhua Pharmaceutical (Chinese: 新华制药,00719:HK) leading the rally on the back of thriving R&D of anti-coronavirus drugs.
Updated 53 mins ago
Briefing Dec 02, 2021 08:29 PM
· Financials
Shanghai Laishi: Kerui Tiancheng investment holding has passively reduced its stake of 2.09%
Briefing Oct 13, 2021 06:53 PM
· Consumer Staples
Shanghai Laishi: Laishi China plans to passively reduce its holdings of no more than 10.24 million shares
Briefing Sep 08, 2021 08:43 PM
Shanghai Laishi: the controlling shareholder and actual controller are changed to none
Briefing Aug 13, 2021 08:13 PM
· Technology
Shanghai Laishi: Kerui Tiancheng and those acting in concert have passively reduced 672 million shares
See more
Related Companies
EqualOcean Analysis
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.